返回 
加入收藏
丁苯酞治疗阿尔茨海默病的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 丁苯酞治疗阿尔茨海默病的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察丁苯酞治疗阿尔茨海默病（AD）的临床疗效及安全性。方法：选取2013年1月－2014年6月我院收治的AD患者94例，按治疗方案分为对照组（45例）和观察组（49例）。对照组患者给予营养神经、降血脂、口服盐酸美金刚片5 mg，bid等常规治疗；观察组患者在对照组基础上口服丁苯酞软胶囊0.2 g，tid。两组患者均连续治疗1年。观察两组患者临床疗效及治疗前后简易精神状态检查表（MMSE）评分、日常生活能力量表（ADL）评分、肿瘤坏死因子（TNF）-α、白细胞介素（IL）-1、血清C反应蛋白（CRP）、脑源性神经营养因子（BDNF）水平，并比较不良反应发生率。结果：观察组患者总有效率为85.71％，显著高于对照组的66.67％，差异有统计学意义（P＜0.05）。两组患者治疗前MMSE和ADL评分比较，差异无统计学意义（P＞0.05），两组患者治疗后MMSE和ADL评分升高，且观察组明显高于对照组，差异有统计学意义（P＜0.05）。两组患者治疗前TNF-α、IL-1、CRP、BDNF水平比较，差异无统计学意义（P＞0.05），两组患者治疗后上述指标均明显改善，且观察组明显优于对照组，差异均有计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：丁苯酞治疗AD疗效显著，能提高患者认知及生活能力、降低炎性因子的水平，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of butylphthalide in the treatment of Alzheimer’s disease （AD）. METHODS： 94 AD patients selected from our hospital during Jan. 2013-Jun. 2014 were divided into control group （45 cases） and observation group （49 cases）. Control group was given routine treatment as ?nourishing nerve， lowering blood lipid， taking Memantine hydrochloride tablet orally 5 mg， bid. Observation group was additionally given Butylphthalide soft capsule orally 0.2 g， tid， on the basis of control group. Both groups were treated for consecutive 1 year. Clinical efficacy of 2 groups were observed， and MMSE， ADL， the levels of TNF-α， IL-1， CRP and BDNF were observed before and after treatment； the incidence of ADR was compared. RESULTS： The total effective rate of observation group was 85.71％， which was significantly higher than that of control group （66.67％）， with statistical significance （P＜0.05）. There was no statistical significance in MMSE and ADL between 2 groups before treatment （P＞0.05）； those of 2 groups increased significantly after treatment， the observation group was higher than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the levels of TNF-α， IL-1， CRP and BDNF between 2 groups before treatment （P＞0.05）. Above indexes of 2 groups were improved significantly after treatment， the observation group was better than the control group， with statistical significance （P＜0.05）. There was no statistical difference in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Butylphthalide is effective in the treatment of AD， can improve cognitive and life skills and reduce inflammatory level with good safety. |
| 期刊： | 2016年第27卷第17期 |
| 作者： | 齐凡星，胡莹，卢军栋，李志安，李恳 |
| AUTHORS： | QI Fanxing，HU Ying，LU Jundong，LI Zhi’an，LI Ken1 |
| 关键字： | 丁苯酞；阿尔茨海默病；安全性；临床疗效 |
| KEYWORDS： | Butylphthalide； Alzheimer’s disease； Safety； Clinical efficacy |
| 阅读数： | 352 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
